Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01754558
Other study ID # SJ-252
Secondary ID
Status Completed
Phase N/A
First received December 28, 2011
Last updated May 1, 2014
Start date May 2012
Est. completion date April 2014

Study information

Verified date May 2014
Source Roskilde County Hospital
Contact n/a
Is FDA regulated No
Health authority Denmark: The Danish National Scientific Board
Study type Interventional

Clinical Trial Summary

During the last decade numerous new procedures have been presented regarding surgical treatment of urinary stress incontinence (1,2). Development of the midurethral tape procedure (TVT) changed the surgical procedure dramatically both regarding the extent of the surgical procedure and also decreased the morbidity remarkably. The success rate of the TVT procedure has been proven to be high (1,2 ). However, the development of the TOT/TVT-O procedures disclosed a new fixation point and further decreased the risk of bladder injury (1,2). Since the introduction of trans-obturator slings several mini-slings have been introduced in order to reduce the need of perforation of the skin and muscles (3,4,5). Although some systems seem promising (5) others have disclosed a long learning curve, pain problems following the procedure and lower success rates, compared to the traditional sling procedures. None of these mini-slings have been adjustable.

Recently the Ajust system for treatment of stress urinary incontinence was introduced. The system is a single incision sling procedure and consists of an adjustable Polypropylene mesh sling with self fixation anchors (6). In a feasibility study (6), the 6 months objective cure rate was 82%, but there is a lack of information regarding adverse events and durability of treatment success. Our preliminary experiences suggest, that the procedure has a rapid learning curve, low pain scores postoperatively and a 94% cure rate at 3 months follow-up (personal observation). Recently, several abstracts have indicated that the cure rate obtained by Ajust is comparable to TVT or TVT-O (10-12).

The purpose of the present study is (primary outcome):

To test the hypothesis that the Ajust and TVT, TVT-O and TOT, respectively are equal regarding subjective cure rate (cure is defined as subjectively not incontinent at all), i.e. the study is designed as a non-inferiority study. The study is performed as a randomised controlled trial without blinding. The study is powered to detect a 9% difference between the two groups. The subjective cure rate is based on ICIQ measurement

Secondary outcome:

- To test the hypothesis that Ajust is associated with a significantly lower postoperative pain perception.

- To test the hypothesis that antibiotic treatment is not necessary


Description:

Primary endpoint: A cured patients is defined as no subjective symptoms (ICIQ-UI SF and ICIQ-OAB) and no objective detectable urinary leakage during coughing (300cc in the bladder and no leakage during coughing)

Secondary outcome: Pain-perception is evaluated by VAS scoring daily during the first postoperative week, including assessing the need for painkilling medication

The endpoint regarding the use of antibiotics is based on the number of urinary tract infections and infections related to the vaginal closure during the first postoperative months. All patients will evaluated postoperative by physical examination and by urinary dipstick


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- 1. A medical history of stress urinary incontinence, i.e. leakage during coughing, sneezing or leakage during physical exertion. OR 2. A medical history of mixed urinary stress incontinence defined as complaint of involuntary leakage associated with urgency and stress incontinence. Stress incontinence has to the dominating symptom defined as more episodes of leakage due to coughing or physical exertion than with urgency.

3. A provocative stress test up to ten coughs at a standardized bladder volume (300 ml) confirming urinary leakage from the urethra while the patient is asked to cough or perform a Valsalva manoeuvre standing or lying (7). Furthermore, the patient has to present hypermobility of the urethra/bladder neck defined as significant downward rotation when coughing or during Valsalva.?

Exclusion Criteria:

1. Previous anti-incontinence surgery.

2. Residual urine volume >100 ml

3. Bladder capacity <200ml according to diary.

4. Planned or current pregnancy

5. Repeated urinary tract infections (>4 cystitis last year )

6. Current anticoagulation therapy that canĀ“t be interrupted in due time prior to surgery

7. Known abnormal coagulation

8. Allergy to local anaesthetics

9. Co-existing pelvic pathology, such as ovarian mass etc

10. Vaginal POPQ anterior prolapse grade >=2

11. A medical history of predominantly urge urinary incontinence.

12. Patients unable to understand the protocol and a follow up

13. Patients younger than 18 and above or equal to 60 years.

14. Known or suspected neurological condition

15. Patients who have not paused acethylsalicylic acid (ASA) medication 7 days prior to surgery

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
Ajust system
The use of Ajust system for stress incontinence
TVT/TVT-O
sling surgery

Locations

Country Name City State
Denmark Martin Rudnicki Roskilde

Sponsors (1)

Lead Sponsor Collaborator
Roskilde County Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other number of urinary tract infections and infections related to the vaginal closure during the first postoperative months. The endpoint regarding the use of antibiotics is based on the number of urinary tract infections and infections related to the vaginal closure during the first postoperative months. All patients will evaluated postoperative by physical examination and by urinary dipstick Evaluated during the first week of follow-up and at 3 months follow-up Yes
Primary A change in number of cured patients Primary endpoint: A change in number of cured patients. The number of patients cured is anticipated to be equal in each group.
A cured patients is defined as having no subjective symptoms (i.e. no scores on the ICIQ-UI SF and ICIQ-OAB) and no objective detectable urinary leakage during coughing (300cc in the bladder and no leakage during coughing.
Up to 1 year Yes
Secondary Pain-perception following surgery Secondary outcome: Pain-perception is evaluated by VAS scoring daily during the first postoperative week, including assessing the need for painkilling medication
The endpoint regarding the use of antibiotics is based on the number of urinary tract infections and infections related to the vaginal closure during the first postoperative months. All patients will evaluated postoperative by physical examination and by urinary dipstick
Evaluated the first week following surgery, and at three and 12 months follow-up Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02867748 - TVT-ABBREVO Versus SERASIS for the Treatment of Female Urinary Stress Incontinence: 1 Year Outcomes of a Comparative Study With 2 Trans-obturator Sub Mid Urethral Slings N/A
Recruiting NCT02617797 - Radiofrequency in the Female Stress Urinary Incontinence N/A
Active, not recruiting NCT02538991 - TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence N/A
Completed NCT02480231 - Mid-Urethral Sling Tensioning Trial N/A
Terminated NCT02591381 - Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT00984958 - Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure N/A
Completed NCT00190567 - Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence Phase 2
Completed NCT02423486 - The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback N/A
Recruiting NCT00136071 - Transvaginal Tension Free Vaginal Tape-Obturator (TVT-O) Versus Transobturator Tape-Mentor (TOT) in the Management of Urodynamic Stress Urinary Incontinence N/A
Completed NCT00190619 - Efficacy and Safety of Duloxetine Phase 3
Completed NCT04288648 - Pelvic Floor Contraction in Different Positions Among Women With and Without Stress Urinary Incontinence
Active, not recruiting NCT05182632 - Tele-rehabilitation Group Program for Urinary Incontinence in Older Women N/A
Completed NCT03672461 - A Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women N/A
Completed NCT02407145 - Safety and Efficacy of PVDF (DynaMesh®-SIS Soft) Retropubic Midurethral Slings in Stress Urinary Incontinence in Women
Completed NCT01784172 - Efficacy and Safety Study of Electroacupuncture for Simple Female Stress Urinary incontinence-a Multicenter Trial Phase 2
Recruiting NCT02935803 - A Study on the Anti-incontinent Effectiveness of the mTVM Method in POPQ Stage II-III Patients N/A
Active, not recruiting NCT02039830 - Group Versus Individual Physiotherapy for Urinary Incontinence in Aging Women N/A
Recruiting NCT04817839 - Optimal Duration of Post-Operative Activity Restriction After Midurethral Sling Procedures N/A
Completed NCT03439527 - Multisystem Cell Therapy for Improvement of Urinary Continence Phase 1
Completed NCT01392651 - Tension-free-vaginal-tape-obturator (TVTO) Versus Tension-free-vaginal-tape-Secur (TVTS) for Treatment of SUI N/A